First published 9/28/2026, 8:20:15 AM · Last updated 9/28/2026, 8:20:15 AM

Psychiatric effects of cannabidiol, cannabinol, and tetrahydrocannabinol: A narrative review of clinical evidence and risk profiles

A Wiley journal article published 2026-07-16 presents a narrative review of clinical evidence and risk profiles for the psychiatric effects of cannabidiol, cannabinol, and tetrahydrocannabinol. The source is identified as a journal article but provides no additional event or location details in the supplied excerpt.

Categories: public-health, science-and-space

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 5/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 3/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 3/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 2/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 5/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 1/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

The review compiles clinical evidence and risk profiles that are relevant to understanding psychiatric effects of these cannabinoids.

Sources

Psychiatric effects of cannabidiol, cannabinol, and tetrahydrocannabinol: A narrative review of clinical evidence and risk profiles

Report an issue